Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.

Vabysmo (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilise blood vessels.1

In Bangladesh Vabysmo is approved for the following indications.2

Vabysmo is a bispecific angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of:

  • Neovascular (wet) age-related macular degeneration (nAMD)

  • Diabetic macular edema (DME)

  • Macular edema secondary to retinal vein occlusion (RVO).

For more disease and medicine related queries you may discuss with your physician.

In Bangladesh Vabysmo is available as
Vials 6 mg/0.05 mL

is the authorized importer and distributor for Roche pharmaceutical medicines in Bangladesh. To meet strict quality and compliance, Radiant maintains temperature controlled supply chain.

To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.

References:

  1. Roche | Vabysmo (faricimab-svoa). [Internet; cited 2024, January 30]. Retrieved from https://www.roche.com/solutions/pharma/productid-0a6b3497-d8a2-4a5f-a2d4-b0ffa5769fea

  2. Vabysmo Product Information RO-6867461 November-2023

This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.